GlassScriptPhysician profile
Stephen J Watts
NPI 1417050642
$7,934.78
in general payments reported to CMS, 2019-2025
26 companies · $758 in 2025
The $758 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,355 · 2020: $758 · 2021: $1,193 · 2022: $1,121 · 2023: $944 · 2024: $805 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,945.45 | 2019-2025 | Ensite, Jot Dx, Agilis |
| Janssen Pharmaceuticals, INC | $1,235.87 | 2019-2024 | Xarelto, Acclaim |
| Boston Scientific Corporation | $1,153.13 | 2019-2025 | General - Ep |
| Medtronic, INC. | $583.72 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Micra, Arctic Front Advance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $468.67 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $427.08 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $296.92 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $272.34 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.82 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $167.12 | 2019-2024 | |
| Altathera Pharmaceuticals LLC | $156.55 | 2023 | Sotalol Hydrochloride |
| Abiomed | $142.26 | 2022 | |
| Pfizer INC. | $141.67 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $123.53 | 2024-2025 | Assure Wcd |
| Atricure, INC. | $103.69 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $77.59 | 2023-2025 | Barostim Neo System |
| Eisai INC. | $75.09 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $71.54 | 2023-2024 | Inpefa |
| Philips North America LLC | $46.66 | 2024 | (Am5) Lead Management |
| Impulse Dynamics (USA) INC. | $44.57 | 2025 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $33.38 | 2022-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $30.23 | 2025 | |
| Biosense Webster, INC. | $27.16 | 2021-2022 | |
| Cardiva Medical, INC. | $24.62 | 2019 | |
| Baxter Healthcare | $24.28 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Cardiovascular Systems INC. | $19.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.